Cargando…

Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling

BACKGROUND: B-cell non-Hodgkin lymphomas (NHL) are hematologic malignancies that arise in the lymph node. Despite this, the malignant cells are not cleared by the immune cells present. The failure of anti-tumor immunity may be due to immune checkpoints such as the PD-1/PDL-1 axis, which can cause T-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenbaum, Adam M., Fromm, Jonathan R., Gopal, Ajay K., Houghton, A. McGarry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242835/ https://www.ncbi.nlm.nih.gov/pubmed/35551108 http://dx.doi.org/10.5045/br.2022.2021145

Ejemplares similares

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Zhang, Wenqi, et al.
Publicado: (2021)

Retracted: Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Markers, Disease
Publicado: (2023)

Diffuse Large B-Cell Lymphoma (DLBCL) in an Aged Raccoon (Procyon lotor)
por: D’Annunzio, Giulia, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma (DLBCL) with significant intravascular invasion. Close resemblance of its clinicopathological features to intravascular large B-cell lymphoma, but not to DLBCL-not otherwise specified
por: Itami, Hiroe, et al.
Publicado: (2021)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021)

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
por: Griffiths, Robert, et al.
Publicado: (2010)

Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL)
por: Markovic, O., et al.
Publicado: (2012)

Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL)
por: Feng, Pengcheng, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
por: Vodicka, Prokop, et al.
Publicado: (2022)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients
por: Nair, Viswam S., et al.
Publicado: (2021)

Human breast tumor-infiltrating CD8(+) T cells retain polyfunctionality despite PD-1 expression
por: Egelston, Colt A., et al.
Publicado: (2018)

SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients
por: Schif, Birgit, et al.
Publicado: (2012)

The fear of lymphadenopathy: A cautionary case of sarcoidosis masquerading as recurrent diffuse large b-cell lymphoma (DLBCL)
por: Whooley, Peter D., et al.
Publicado: (2018)

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
por: Regier, Dean A., et al.
Publicado: (2022)

P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
por: Jiang, Y., et al.
Publicado: (2022)

Polymorphisms in DNA Repair and One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma
por: Wang, Sophia S, et al.
Publicado: (2008)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
por: Dunleavy, K, et al.
Publicado: (2009)

The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy
por: Coughlan, Monica, et al.
Publicado: (2014)

Extra- and Intracranial Diffuse Large B-Cell Lymphoma (DLBCL) Mimicking Meningioma: A Case Report and Literature Review
por: Matejka, Matthias, et al.
Publicado: (2023)

MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8(+) T lymphocytes in human diffuse large B cell lymphoma
por: Xu, Yangyang, et al.
Publicado: (2020)

Virus-specific CD8+ T cells infiltrate melanoma lesions and retain function despite high PD-1 expression
por: Erkes, Dan A, et al.
Publicado: (2015)

A Multi-institutional Analysis of Diffuse Large B-cell Lymphoma (DLBCL) Treated with Consolidative Radiotherapy and the Impact of Cell-of-origin on Outcomes
por: Rajasooriyar, Chrishanthi, et al.
Publicado: (2019)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Illidge, T., et al.
Publicado: (2022)

Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis
por: Hone Lopez, Sara, et al.
Publicado: (2021)

Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL
por: Bhalla, Kavita, et al.
Publicado: (2018)

Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy
por: Klimiuk, Paweł, et al.
Publicado: (2021)

Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China
por: Sun, Jian-Jun, et al.
Publicado: (2020)

Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis
por: Tsutsué, Saaya, et al.
Publicado: (2022)

PB2152: BIOLOGICAL AND CLINICAL CORRELATES OF GALECTIN-3 (GAL-3) EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Basic-Kinda, S., et al.
Publicado: (2022)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Cancer-Associated Fibroblasts Suppress CD8(+) T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade
por: Jenkins, Liam, et al.
Publicado: (2022)

Profiling of coexpression of multiple immune checkpoints in the CD4+ and CD8+ T cell components of the clear cell renal cell carcinoma immune infiltrate
por: Monette, Anne, et al.
Publicado: (2015)

Prevalence of Anti-Citrullinated Protein Antibodies (ACPA) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Case-Control Study
por: Assmann, Gunter, et al.
Publicado: (2014)

Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database
por: Zhou, Chunhui, et al.
Publicado: (2021)

A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy
por: Wang, Ping, et al.
Publicado: (2023)

PB2293: REAL WORLD STUDY OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE ELDERLY: FOURTEEN YEARS OF ONE CENTER’S EXPERIENCE
por: De Ascanio, Victoria Ramos, et al.
Publicado: (2023)

PB2376: ASSAY DEVELOPMENT AND VALIDATION OF IG-HTS TO MONITOR MRD IN PLASMA OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Wu, Jinghua, et al.
Publicado: (2023)

Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses
por: Lyudovyk, Olga, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qprk2bjv8flv9k072j06nrtp8d